Any halo earned from helping tackle the Covid-19 pandemic is likely to be short-lived for big pharma, according to asset managers who are turning their sights towards biotech and telehealth as the world slowly returns to normal.
On 8 December 2020, England became the first country to roll out a Covid-19 vaccine, a jab developed by Pfizer and BioNTech. In the months leading up to that, the healthcare sector took a leading role during the Covid-19 pandemic, with many investors backing firms that work to develop treatments for the virus. But now that more than 32 million people in the UK have received at least their first dose, the market is moving on. Investing in biotech: Where are we now and what is the outlook? For Peter Choi, senior research analyst at Vontobel, big pharma is sailing towards trouble. ...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
